Cell and Gene Therapy in the Time of COVID-19 – Imperative for Innovation
Webinar
Date
May 27, 2020
11:00AM - 12:00PM (GMT -04:00) Eastern Daylight Time
Calendar

Cell and Gene Therapy may be a potential weapon in the therapeutic armamentarium for the novel coronavirus disease (COVID-19). Join our upcoming webinar to learn about the application of Cell and Gene Therapy (CAGT) to COVID-19. We will share real-time clinical insights on the pandemic and the COVID-19 CAGT clinical trial landscape mined from IQVIA data. We will explore how CAGT is being applied to treat the disease and discuss key study design and operational considerations for new CAGT trials. Finally, we will review the impact of COVID-19 on the CAGT clinical trial environment and share lessons learned conducting CAGT trials during the early period of the COVID-19 pandemic that may help plan for the future.

Key take-aways:

  • Gain real-time insights into the current clinical landscape for COVID-19
  • Learn how CAGT therapies are being applied to treat of COVID-19
  • Review key study design and operational considerations for COVID-19 CAGT trials
  • Review best practices for managing ongoing CAGT trials in the environment of COVID-19 and discuss strategies to risk mitigate for the future
Speakers

Dr. Monica R. Shah, MD, FACC

Vice President Medical Strategy, Head Cell and Gene Therapy Center of Excellence and Cardiovascular Center of Excellence, IQVIA

Dr. Chris A. Learn, Ph.D., PMP

Sr. Therapeutics Strategy, Director, Cell and Gene Therapy Center of Excellence and Cardiovascular Center of Excellence, IQVIA

Tanya Partridge BSc

Global Solutions Manager, Data Sciences Lead for the Cell and Gene Therapy Center of Excellence, IQVIA
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.

Media Inquiries

Please use this form to reach out to our media team with inquiries. Thank you.